Drugs.com - Clinical Trials

Genasense Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma

Fri, 20 Nov 2009 20:55:42 GMT

Data Presented at International Melanoma Conference in Berlin Results Follow Decision by Company to Continue Phase 3 AGENDA Trial for Overall Survival BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Nov 20, 2009 - Genta Incorporated (OTCBB:...

Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting

Fri, 20 Nov 2009 13:11:42 GMT

SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at...

Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies

Fri, 20 Nov 2009 12:53:11 GMT

Inovio's SynConTM Universal Flu Vaccines Provide 100% Protection in Ferrets against Death and Sickness in a Challenge Study with the Pandemic H1N1 Virus SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Inovio Biomedical Corporation (NYSE Amex:INO), a...

Military Study Shows Prevention of Novel A/H1N1 Virus Infection is Vaccine-Type and Age-Dependent

Thu, 19 Nov 2009 19:58:15 GMT

Both Live, Attenuated Influenza Vaccine (LAIV) and Trivalent Inactivated Vaccine (TIV) provide Protection against novel A/H1N1, especially against severe disease WASHINGTON, Nov. 19 /PRNewswire/ -- Immunization with either live attenuated influenza...

Positive Results from Chronic Study with Bayer ?s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009

Thu, 19 Nov 2009 19:10:21 GMT

Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE Berlin, November 19, 2009 -...

VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile

Thu, 19 Nov 2009 13:56:22 GMT

Results Underscore Differentiating Profile; Indicate Significant Market Opportunity for Avanafil MOUNTAIN VIEW, Calif., Nov. 18 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced positive results from REVIVE (TA-301), a phase 3...

Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.

Thu, 19 Nov 2009 13:51:10 GMT

SAN FRANCISCO, Nov. 18 /PRNewswire/ -- Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority...

ImmuPharma announces Positive Ph2b Lupuzor trial results

Thu, 19 Nov 2009 13:11:55 GMT

ENCOURAGING FINAL PHASE IIb RESULTS SEEN WITH LUPUZOR™ IN SYSTEMIC LUPUS ERYTHEMATOSUS ~ Greatest benefits seen in patients with moderate to severe Systemic Lupus Erythematosus ~ LONDON, Nov. 19, 2009-ImmuPharma PLC (LSE: IMM) the...

Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conference

Thu, 19 Nov 2009 13:11:22 GMT

Basel, Switzerland, November 19, 2009 - Basilea Pharmaceutica Ltd. (SIX:BSLN) presents new research data on its innovative antitumor drug candidate BAL27862 at the international conference on Molecular Targets and Cancer Therapeutics in Boston...

Medivir: Epiphany Biosciences Announces Positive Results from Its Phase 2b Trial in Shingles

Thu, 19 Nov 2009 12:52:17 GMT

STOCKHOLM--(BUSINESS WIRE)--Nov 19, 2009 - Regulatory News: Medivir (STO:MVIRB): The Epiphany Biosciences press release reads as follows; Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir)...

Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC

Thu, 19 Nov 2009 12:46:33 GMT

Dosing Schedule of Imetelstat Achieves Drug Exposure Consistent with In Vivo Inhibition of Tumor Growth MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 19, 2009 - Geron Corporation (Nasdaq:GERN) today announced the presentation of interim data from its...

Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090

Wed, 18 Nov 2009 21:17:05 GMT

- Broad anti-cancer activity as a single agent and in combination - Strong potency against highly resistant cancers - Superior profile to first generation Hsp90 inhibitors LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 -...

Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Wed, 18 Nov 2009 21:12:03 GMT

Copper redox reaction key to elesclomol's ability to generate ROS LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and...

Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS

Wed, 18 Nov 2009 20:45:11 GMT

RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based...

Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body

Wed, 18 Nov 2009 20:41:18 GMT

Ticagrelor data presented at the American Heart Association Scientific Sessions ORLANDO, Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for...

Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference

Wed, 18 Nov 2009 20:17:08 GMT

- In Preclinical Studies, Peregrine's PS-Targeting Antibodies Including Bavituximab Demonstrated Broad Spectrum Binding to Viruses and Virally Infected Cells Representing Three Viral Hemorrhagic Fever (VHF) Families - - Preclinical Efficacy...

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference

Wed, 18 Nov 2009 20:01:25 GMT

BOSTON--(BUSINESS WIRE)--Nov 18, 2009 - Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid...

Cardiovascular Outcomes with Ezetimibe and Simvastatin Similar to Statin Alone, Claims Data Suggest

Wed, 18 Nov 2009 20:00:49 GMT

Retrospective Analysis of Almost 30,000 Patients Shows No Significant Difference in Risk of Heart Attack or Stroke with Monotherapy Compared With Combination Therapy IRVINE, Calif.--(BUSINESS WIRE)--Nov 18, 2009 - Prescription Solutions, a leading...

Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results

Wed, 18 Nov 2009 19:57:26 GMT

Data to be presented at 12th Congress of the European Society for Sexual Medicine, November 15th to 18th, Lyon SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has...

Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302

Wed, 18 Nov 2009 19:43:01 GMT

Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302 REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to...

Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients

Wed, 18 Nov 2009 17:20:02 GMT

VT-111 significantly reduces key cardiac enzymes at multiple time points after stent placement; Data presented at American Heart Association 2009 Scientific Sessions LONDON, ON, Nov. 18 /PRNewswire/ -- Viron Therapeutics Inc., a biotechnology...

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder

Wed, 18 Nov 2009 13:30:50 GMT

CAMBRIDGE, Mass., Nov. 18, 2009-Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels...

ImmunoGen Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma

Wed, 18 Nov 2009 13:27:02 GMT

WALTHAM, MA, November 17, 2009 – ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of Merkel...

Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association

Wed, 18 Nov 2009 13:22:37 GMT

FREMONT, Calif., Nov 18, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's...

Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer

Wed, 18 Nov 2009 12:57:20 GMT

- New Results Demonstrate Robust Anti-Tumor Activity in Multiple Models, Including Extra-Hepatic Tumors - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company,...

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder

Wed, 18 Nov 2009 12:57:05 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB...

YM Biosciences Reports Cyt997 Oral Vascular Disrupting Agent Results Presented At AACR-NCI-EORTC Meeting

Tue, 17 Nov 2009 20:27:13 GMT

MISSISSAUGA, ON, November 17, 2009 /PRNewswire-FirstCall/ - YM BioSciences Inc. , a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development,...

American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure Patients

Tue, 17 Nov 2009 20:20:19 GMT

Study highlights: -- Iron treatment with intravenous (I.V.) ferric carboxymaltose significantly improved symptoms, functional capacity and quality of life for Class II and III chronic heart failure (CHF) patients. -- This treatment worked equally...

Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual Meeting

Tue, 17 Nov 2009 20:15:34 GMT

INDIANAPOLIS--(BUSINESS WIRE)--Nov 16, 2009 - Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals' lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the...

BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction

Tue, 17 Nov 2009 20:15:32 GMT

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nov 16, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire...

Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile

Tue, 17 Nov 2009 20:15:09 GMT

Results Will Be Presented Today At AHA Conference in Orlando, Florida BRIDGEWATER, N.J.--(BUSINESS WIRE)--Nov 16, 2009 - Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic...

Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD

Tue, 17 Nov 2009 20:10:57 GMT

Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured Efficacy Parameters HAIFA, Israel--(BUSINESS WIRE)--Nov 17, 2009 - Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that safety and potential efficacy...

Higher Dose of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study

Tue, 17 Nov 2009 20:10:30 GMT

Results from HEAAL Study Presented as Late-Breaker at American Heart Association Scientific Sessions 2009 ORLANDO, Fla.--(BUSINESS WIRE)--Nov 17, 2009 - In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg,...

NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors

Tue, 17 Nov 2009 20:10:27 GMT

LAKE BLUFF, Ill.--(BUSINESS WIRE)--Nov 17, 2009 - NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International...

Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions

Tue, 17 Nov 2009 20:10:14 GMT

Persistent Lipid Effects Remained in the Higher Dose Arms After Cessation Of Therapy in Patients with Dyslipidemia ORLANDO, Fla.--(BUSINESS WIRE)--Nov 17, 2009 - In a phase IIb study in 589 patients with primary hypercholesterolemia or...

Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009

Tue, 17 Nov 2009 20:10:04 GMT

Lead Investigator for Provectus' PV-10 Trial Will Present At 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin Will Update Compassionate Use Program KNOXVILLE, Tenn.--(BUSINESS WIRE)--Nov 17, 2009 -...

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference

Tue, 17 Nov 2009 19:37:33 GMT

BOSTON--(BUSINESS WIRE)--Nov 17, 2009 - Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid...

ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma

Tue, 17 Nov 2009 19:32:29 GMT

WALTHAM, Mass.--(BUSINESS WIRE)--Nov 17, 2009 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment...

AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting

Tue, 17 Nov 2009 19:32:23 GMT

Preclinical Combination Data Also Presented, Demonstrate mTOR-Tivozanib Combination in Breast Tumor Model Prevents Emergence of Resistance CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 17, 2009 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company...

Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results

Tue, 17 Nov 2009 19:21:51 GMT

- Data Presented at AACR-NCI-EORTC's "Molecular Targets and Cancer Therapeutics" International Conference - SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today announced updated...